Samira M Sadowski1, Corina Millo2, Candice Cottle-Delisle3, Roxanne Merkel3, Lily A Yang3, Peter Herscovitch2, Karel Pacak4, William F Simonds5, Stephen J Marx5, Electron Kebebew3. 1. Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: samira.sadowskiveuthey@nih.gov. 2. Positron Emission Tomography Department, Warren Grant Magnusson Clinical Center, National Institutes of Health, Bethesda, MD. 3. Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. 4. Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of Health, Bethesda, MD. 5. Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Abstract
BACKGROUND: Screening for neuroendocrine tumors (NETs) in patients with multiple endocrine neoplasia type 1 (MEN1) is recommended to detect primary and metastatic tumors, which can result in significant morbidity and mortality. The utility of somatostatin receptor imaging (68)Gallium-DOTATATE PET/CT in patients with MEN1 is not known. The aim of this study was to prospectively determine the accuracy of (68)Gallium-DOTATATE PET/CT vs (111)In- pentetreotide single-photon emission CT (SPECT)/CT and anatomic imaging in patients with MEN1. STUDY DESIGN: We performed a prospective study comparing (68)Gallium-DOTATATE PET/CT, (111)In-pentetreotide SPECT/CT, and triphasic CT scan to clinical, biochemical, and pathologic data in 26 patients with MEN1. RESULTS: (68)Gallium-DOTATATE PET/CT detected 107 lesions; (111)In-pentetreotide SPECT/CT detected 33 lesions; and CT scan detected 48 lesions. Lesions detected on (68)Gallium-DOTATATE PET/CT had high standard uptake value (SUV)(max) (median SUV(max) = 72.8 [range 19 to 191]). In 7 of the 26 patients (27%), (68)Gallium-DOTATATE PET/CT was positive, with a negative (111)In-pentetreotide SPECT/CT, and in 10 patients (38.5%), additional metastases were detected (range 0.3 cm to 1.5 cm). In 8 of the 26 patients (31%), there was a change in management recommendations as a result of the findings on (68)Gallium-DOTATATE PET/CT that were not seen on (111)In-pentetreotide SPECT/CT and CT scan. CONCLUSIONS: (68)Gallium-DOTATATE PET/CT is more sensitive for detecting NETs than (111)In-pentetreotide SPECT/CT and CT scan in patients with MEN1. This imaging technique should be integrated into radiologic screening and surveillance of patients with MEN1 because it can significantly alter management recommendations. Published by Elsevier Inc.
BACKGROUND: Screening for neuroendocrine tumors (NETs) in patients with multiple endocrine neoplasia type 1 (MEN1) is recommended to detect primary and metastatic tumors, which can result in significant morbidity and mortality. The utility of somatostatin receptor imaging (68)Gallium-DOTATATE PET/CT in patients with MEN1 is not known. The aim of this study was to prospectively determine the accuracy of (68)Gallium-DOTATATE PET/CT vs (111)In- pentetreotide single-photon emission CT (SPECT)/CT and anatomic imaging in patients with MEN1. STUDY DESIGN: We performed a prospective study comparing (68)Gallium-DOTATATE PET/CT, (111)In-pentetreotide SPECT/CT, and triphasic CT scan to clinical, biochemical, and pathologic data in 26 patients with MEN1. RESULTS: (68)Gallium-DOTATATE PET/CT detected 107 lesions; (111)In-pentetreotide SPECT/CT detected 33 lesions; and CT scan detected 48 lesions. Lesions detected on (68)Gallium-DOTATATE PET/CT had high standard uptake value (SUV)(max) (median SUV(max) = 72.8 [range 19 to 191]). In 7 of the 26 patients (27%), (68)Gallium-DOTATATE PET/CT was positive, with a negative (111)In-pentetreotide SPECT/CT, and in 10 patients (38.5%), additional metastases were detected (range 0.3 cm to 1.5 cm). In 8 of the 26 patients (31%), there was a change in management recommendations as a result of the findings on (68)Gallium-DOTATATE PET/CT that were not seen on (111)In-pentetreotide SPECT/CT and CT scan. CONCLUSIONS: (68)Gallium-DOTATATE PET/CT is more sensitive for detecting NETs than (111)In-pentetreotide SPECT/CT and CT scan in patients with MEN1. This imaging technique should be integrated into radiologic screening and surveillance of patients with MEN1 because it can significantly alter management recommendations. Published by Elsevier Inc.
Authors: Andrea Frilling; Georgios C Sotiropoulos; Arnold Radtke; Massimo Malago; Andreas Bockisch; Hilmar Kuehl; Jun Li; Christoph E Broelsch Journal: Ann Surg Date: 2010-11 Impact factor: 12.969
Authors: Omar Alonso; Mónica Rodríguez-Taroco; Eduardo Savio; Cecilia Bentancourt; Juan P Gambini; Henry Engler Journal: Ann Nucl Med Date: 2014-05-27 Impact factor: 2.668
Authors: Alexander R Haug; Ramona Cindea-Drimus; Christoph J Auernhammer; Martin Reincke; Felix Beuschlein; Björn Wängler; Christopher Uebleis; Gerwin P Schmidt; Christine Spitzweg; Peter Bartenstein; Marcus Hacker Journal: Radiology Date: 2013-10-28 Impact factor: 11.105
Authors: Nils F Schreiter; Winfried Brenner; Munenobu Nogami; Ralph Buchert; Alexander Huppertz; Ulrich-Frank Pape; Vikas Prasad; Bernd Hamm; Martin H Maurer Journal: Eur J Nucl Med Mol Imaging Date: 2011-09-17 Impact factor: 9.236
Authors: M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx Journal: J Clin Endocrinol Metab Date: 2001-12 Impact factor: 5.958
Authors: Michael S Hofman; Grace Kong; Oliver C Neels; Peter Eu; Emily Hong; Rodney J Hicks Journal: J Med Imaging Radiat Oncol Date: 2012-02 Impact factor: 1.735
Authors: Ronald C Walker; Gary T Smith; Eric Liu; Brandon Moore; Jeff Clanton; Michael Stabin Journal: J Nucl Med Date: 2013-03-20 Impact factor: 10.057
Authors: Angela Spanu; Orazio Schillaci; Bastiana Piras; Diego F Calvisi; Antonio Falchi; Roberta Danieli; Susanna Nuvoli; Franca Dore; Giuseppe Madeddu Journal: Am J Nucl Med Mol Imaging Date: 2017-09-01
Authors: Max B Albers; Damiano Librizzi; Caroline L Lopez; Jerena Manoharan; Jonas C Apitzsch; Emily P Slater; Carmen Bollmann; Peter H Kann; Detlef K Bartsch Journal: World J Surg Date: 2017-06 Impact factor: 3.352
Authors: Ingo Janssen; Clara C Chen; Corina M Millo; Alexander Ling; David Taieb; Frank I Lin; Karen T Adams; Katherine I Wolf; Peter Herscovitch; Antonio T Fojo; Inga Buchmann; Electron Kebebew; Karel Pacak Journal: Eur J Nucl Med Mol Imaging Date: 2016-03-21 Impact factor: 9.236